Bortezomib Treatment Produces Nocifensive Behavior and Changes in the Expression of TRPV1, CGRP, and Substance P in the Rat DRG, Spinal Cord, and Sciatic Nerve

Table 4

Percentage (±confidence limits) of TRPV1/neuropeptide DRG neurons in BTZ-treated rats.

Acute BTZ-treatment
	Ctrl	BTZ
TRPV1/CGRP	43.68 ± 0.06%; (58 colocalized/87 TRPV1)	49.43 ± 0.11%; (43 colocalized/87 TRPV1)
CGRP/TRPV1	39.58 ± 0.10%; (58 colocalized/96 CGRP)	41.35 ± 0.01%; (38 colocalized/104 CGRP)
TRPV1/SP	43.53 ± 0.11%; (37 colocalized/85 TRPV1)	32.33 ± 0.06 %*; (86 colocalized/266 TRPV1)
SP/TRPV1	35.92 ± 0.1%; (37 colocalized/103 SP)	44.10 ± 0.07%§; (86 colocalized/195 SP)
Chronic BTZ-treatment
	Ctrl	BTZ
TRPV1/CGRP	43.86 ± 0.092%; (50 colocalized/114 TRPV1)	36.84 ± 0.11%; (28 colocalized/76 TRPV1)
CGRP/TRPV1	36.76 ± 0.003%; (50 colocalized/136 CGRP)	27.72 ± 0.09%§§; (28 colocalized/101 CGRP)
TRPV1/SP	43.33 ± 0.1%; (39 colocalized/90 TRPV1)	24.81 ± 0.07%**; (33 colocalized/133 TRPV1)
SP/TRPV1	50.00 ± 0.006%; (39 colocalized/78 SP)	61.11 ± 0.13%; (33 colocalized/54 SP)

𝑃 value of ctrl rat versus BTZ-treated rat colocalization degree: ^§𝑃=0.090; ^§§𝑃=0.072; ^∗𝑃≤0.05; ^∗∗𝑃=0.0016.